Home » About SARC » History
Analysis of multiple SARC trials to understand chemotherapy response in more common sarcomas.
Phase III Abemaciclib vs. Placebo in Advanced Dedifferentiated Liposarcoma
ABOUT THIS TRIAL
Phase II study of Regorafenib and Nivolumab in Osteosarcoma
Understanding Adoptive Cell Therapy for Sarcoma
Phase I Trabectedin plus Irinotecan and (18F-FLT) Imaging in Ewings SarcomaA Phase I study to evaluate the safety of Trabectedin administered as a one hour infusion in Ewing Sarcoma patients in combination with low dose Irinotecan and 3′-Deoxy-3′-18F Fluorothymidine (18F-FLT) imaging.
Jonathan Fletcher, MD
Steven YoungREAD BIO
Sarcoma patient advocacy foundations working together.
Phase II Pembrolizumab (MK-3475) for Advanced SarcomasFirst study to test immune checkpoint inhibitors in advanced sarcoma.
Oral Regorafenib in Selected Sarcoma SubtypesFirst active systemic therapy in metastatic Osteosarcoma in 30 years.
Phase III TH-302 with Doxorubicin vs. Doxorubicin Alone in Soft Tissue SarcomaFirst phase III trial in over 100 centers.
Awarded five-year Sarcoma Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute. The first such award in any cancer type that connected multiple cancer centers to work collaboratively.
ABOUT SARCOMA SPORE
Research grants awarded to early-stage, young physicians/scientists dedicated to defeating sarcoma.
ABOUT THE CAREER DEVELOPMENT PROGRAM
Phase II R1507 in Recurrent or Refractory SarcomaFirst international clinical trial.
Phase II Imatinib Mesylate in Soft Tissue and Bone SarcomasFirst SARC clinical trial.
Sign up for our monthly SARC newsletter and updates on clinical trials.